Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.50 |
| ▸ | GCK | P35557 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678422 | 1.00 | NR1H4 (0.51) | NR1H4MRGPRX4GCKNR4A2MEN1 | |
| SCHEMBL6674936 | 0.90 | GCK (0.53) | NR1H4GCKNR4A2MEN1KMT2A | |
| SCHEMBL6674932 | 0.90 | GCK (0.53) | NR1H4GCKNR4A2MEN1KMT2A | |
| SCHEMBL6674556 | 0.84 | LTC4S (0.45) | MEN1KMT2ALTC4S | |
| SCHEMBL6674560 | 0.84 | LTC4S (0.45) | MEN1KMT2ALTC4S | |
| SCHEMBL6677951 | 0.81 | KDM4E (0.58) | MEN1KMT2A | |
| SCHEMBL6677957 | 0.81 | KDM4E (0.58) | MEN1KMT2A | |
| SCHEMBL6674346 | 0.80 | MEN1 (0.62) | MEN1KMT2ALTC4SHDAC1 | |
| SCHEMBL6673496 | 0.80 | MEN1 (0.62) | MEN1KMT2ALTC4SHDAC1 | |
| SCHEMBL6676810 | 0.79 | MEN1 (0.61) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032218-A1 | Substituted stilbenes as glucose uptake enhancers | TELIK, INC. | 2002-03-14 | — | — | US | claimed |
| EP-1289936-B1 | SUBSTITUTED STILBENES AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6479548-B2 | P-(BENZOYLAMINO)STILBENE DERIVATIVES | TELIK, INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020032218-A1 | Substituted stilbenes as glucose uptake enhancers | TELIK, INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032218-A1 | Substituted stilbenes as glucose uptake enhancers | SLC2A1, SLC2A8, SLC2A2 | NR1H4 856/4885MRGPRX4 1150/4885GCK 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.